CSIMarket
 
Bicycle Therapeutics Plc  (BCYC)
Other Ticker:  
 
 
Price: $24.1200 $0.36 1.515%
Day's High: $24.4 Week Perf: -3.67 %
Day's Low: $ 23.01 30 Day Perf: 9.19 %
Volume (M): 374 52 Wk High: $ 28.91
Volume (M$): $ 9,016 52 Wk Avg: $20.84
Open: $23.76 52 Wk Low: $12.54



 Market Capitalization (Millions $) 858
 Shares Outstanding (Millions) 36
 Employees -
 Revenues (TTM) (Millions $) 27
 Net Income (TTM) (Millions $) -181
 Cash Flow (TTM) (Millions $) 188
 Capital Exp. (TTM) (Millions $) 3

Bicycle Therapeutics Plc
Bicycle Therapeutics Plc is a biotechnology company that specializes in the development of small molecule drugs based on its proprietary Bicycle technology platform. The company is based in the United Kingdom and was founded in 2009.

Bicycle Therapeutics' technology platform is focused on designing and developing bicyclic peptides, which are small and highly specific molecules that can target and bind to disease-causing proteins. These peptides are derived from natural molecules such as hormones and can be modified to enhance their properties.

The company's lead product candidate, BT1718, is being developed for the treatment of solid tumors. BT1718 is a bicyclic peptide-drug conjugate that selectively targets tumors while sparing healthy tissues, potentially reducing side effects associated with chemotherapy.

Bicycle Therapeutics has also entered into partnerships and collaborations with other pharmaceutical companies to further develop its technology platform and advance its pipeline of drug candidates. These partnerships include collaborations with AstraZeneca, Bioverativ, and Cancer Research UK.

Overall, Bicycle Therapeutics Plc is a biotechnology company focused on developing innovative therapies using its proprietary Bicycle technology platform.


   Company Address: Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge 0
   Company Phone Number: 1223 261503   Stock Exchange / Ticker: 0 BCYC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Bicycle Therapeutics Set to Redefine Cancer Treatment Landscape with Trailblazing Therapies at 2024 AACR Annual Meeting

Published Tue, Mar 5 2024 9:35 PM UTC

Bicycle Therapeutics to Showcase Groundbreaking Therapies at 2024 AACR Annual MeetingCAMBRIDGE, England & BOSTON - Bicycle Therapeutics plc (NASDAQ: BCYC), a trailblazing biopharmaceutical company specializing in innovative therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, is thrilled to announce the acceptance of three abstracts for presentation a...

Bicycle Therapeutics Plc

Bicycle Therapeutics Pedals to Success with 67% Revenue Growth in Q4 2023

The financial results for Bicycle Therapeutics Plc for the fourth quarter of 2023 paint an interesting picture of the company's performance. While the net shortfall widened to $-49.099 million compared to $-29.978 million in the prior year, there was a significant improvement in revenue, which grew by 67.378% to $5.33 million from $3.19 million in the comparable quarter a year ago.
It is worth noting that in a time when many companies in the Major Pharmaceutical Preparations industry are experiencing revenue declines, Bicycle Therapeutics Plc has managed to buck the trend and post a strong top-line improvement. This indicates that the company is making strides in its market and attracting attention despite challenges faced by its peers.

Bicycle Therapeutics Plc

Bicycle Therapeutics Plc Achieves Impressive 76.053% Revenue Growth in Q3 2023, Defying Market Challenges

Bicycle Therapeutics Plc, a biotechnology company, has shown significant growth and improvement in its recent financial results for the third quarter of 2023. Despite the challenging market environment, the company has made remarkable strides in expanding their earnings and improving their revenue.
Compared to the previous year, Bicycle Therapeutics has expanded its earnings per share from $-0.96 to $-1.26 per share. This improvement is a testament to the company's commitment to innovation and their ability to adapt to changing market conditions. Furthermore, their earnings per share of $-1.41 from the preceding financial reporting period have also shown improvement.

Bicycle Therapeutics Plc

1. Pharma Giant, Major Pharmaceutical Preparations, Struggles to Profit Despite Massive Revenue Surge in Fiscal 2023!

BCYC, a prominent player in the biotech industry, has recently announced a remarkable surge in revenue for the second quarter of the 2023 earnings season. The company reported a staggering rise of 160.324% year on year, reaching a record high of $11.40 million. Although the per-share shortfall increased to $-1.41, compared to the preceding reporting season, where it was $-1.30, the substantial revenue growth cannot be overlooked.
In the previous reporting season, BCYC experienced a doubled revenue of 132.782% from $4.90 million, showcasing the company's consistent growth and performance. Despite the increased shortfall per share, it is evident that BCYC has been successful in generating revenue and expanding its operations.

Bicycle Therapeutics Plc

Bicycle Therapeutics Plc Powers Through Pandemic Impact with Impressive 26.839% Surge in Q1 2023 Revenue

Bicycle Therapeutics Plc, more commonly known as BCYC, has recently announced an increase in revenue by 26.839% to $4.90 million for the January to March 31 2023 period. This rise in revenue signifies the growing success of the company in recent months as it rebounds from the impacts of the global pandemic. However, the announcement also comes with a caveat - the company has reported an increase in its shortfall per share, at $-1.30 per share.
This is compared to the previous financial reporting period, where BCYC had a shortfall per share of $-0.87. Despite the increased loss per share, the company's revenue has surged by 53.721% from $3.19 million the year before.






 

Bicycle Therapeutics Plc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bicycle Therapeutics Plc does not provide revenue guidance.

Earnings Outlook
Bicycle Therapeutics Plc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com